Standardized criteria for diagnosis and response assessment are needed to interpret and
compare clinical trials and for approval of new therapeutic agents by regulatory agencies. …

Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis 1 ,
2 , 3 . We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an …

Background The intensity of chemotherapy and need for additional radiotherapy in patients
with advanced stage Hodgkin's lymphoma has been unclear. We did a prospective …

Background The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic
agents, has been shown to prolong overall survival in physically fit patients with previously …

We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest
human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 …

The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

MULTIPLE MYELOMA (MM) is a clonal B-cell neo-plasm that affects terminally differentiated
B cells (ie, plasma cells) and may proceed through different phases: an inactive phase in …

Background On the basis of promising results that were reported in several phase 2 trials,
we investigated whether the addition of the monoclonal antibody rituximab to first-line …

Background Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically
significant coexisting medical conditions are less able to undergo standard chemotherapy. …

Which genetic alterations drive tumorigenesis and how they evolve over the course of
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …